3 February 2026 News Release Pharma Equity Group2026 Financial Calendar ​March 4Deadline for shareholder proposals - Annual General meeting​ ​March 18 ​Annual Report 2025​ April 16Annual General Meeting​ August 14Interim Report – for the six-month period ended June 30. 2026​ ​Contact person – Investor Relations On the Company’s website www.pharmaequitygroup.com further information and all published announcements can be found. Inquiries regarding relations with investors and the stock market can be directe ...

Core Viewpoint - Reponex Pharmaceuticals A/S has received regulatory approval to initiate a pivotal Phase 2 clinical trial for RNX-011, targeting secondary peritonitis, a serious intra-abdominal infection with high mortality rates [2][3]. Group 1: Regulatory Approval and Study Design - The approval marks a significant milestone for the company and validates the scientific strategy behind RNX-011 [3]. - The study is a randomized, placebo-controlled trial that will investigate a triple-action combination therapy (fosfomycin, metronidazole, and GM-CSF) administered directly into the abdominal cavity during surgery [4]. - The trial aims to enroll 32 patients, with the first patient expected to be included in Q4 2025 [6]. Group 2: Study Objectives and Expected Outcomes - The primary objective of the study is to demonstrate that RNX-011 can reduce serious postoperative complications, such as abscesses and the need for re-operation, which are critical for potential partners and payers [5]. - The study will also assess the treatment's effect on local inflammation (IL-6) and overall patient recovery (QoR-15) to provide strong mechanistic data supporting clinical efficacy [5]. Group 3: Company Strategy and Future Outlook - The regulatory approval is viewed as a crucial commercial milestone, transitioning from proof-of-concept to a pivotal study that aims to deliver data required by major pharmaceutical companies [7]. - Pharma Equity Group is committed to supporting Reponex Pharmaceuticals in advancing its medical projects, focusing on innovative solutions and breakthrough therapies [9][10].